Whittier Trust Co. Lowers Position in Pfizer Inc. (NYSE:PFE)

Whittier Trust Co. lessened its stake in Pfizer Inc. (NYSE:PFE) by 6.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 193,274 shares of the biopharmaceutical company’s stock after selling 13,365 shares during the period. Whittier Trust Co.’s holdings in Pfizer were worth $5,126,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Retirement Wealth Solutions LLC purchased a new stake in Pfizer in the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $28,000. Noble Wealth Management PBC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PFE. Citigroup reduced their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. UBS Group reduced their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Down 0.2 %

Shares of PFE opened at $26.17 on Friday. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a market capitalization of $148.29 billion, a PE ratio of 18.56, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The stock has a fifty day simple moving average of $26.18 and a two-hundred day simple moving average of $27.07. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the company earned $0.10 EPS. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.